Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Melioidosis
100%
Novel Therapeutics
100%
Therapeutic Candidates
100%
Oral Treatment
100%
Biothreat Pathogens
100%
Pseudomallei
80%
Etiological Agents
20%
Burkholderia Pseudomallei
20%
Inhalational
20%
Mortality Rate
20%
Bacillus Anthracis
20%
Yersinia Pestis
20%
Burkholderia Mallei
20%
Gram-negative Bacteria
20%
Antibiotics
20%
Dose Effect
20%
Acute Phase
20%
Francisella Tularensis
20%
Ceftazidime
20%
In Vivo Efficacy
20%
Healthcare
20%
Lethal Dose 50 (LD50)
20%
Lethal Dose
20%
Resistance Development
20%
Oral Administration
20%
Resistant Strains
20%
Inhibitory Activity
20%
Septicemia
20%
Current Therapies
20%
Outpatient Treatment
20%
Bacterial Topoisomerases
20%
Acute Phase Treatment
20%
Oral Therapeutics
20%
Medicine and Dentistry
Melioidosis
100%
Pathogen
100%
Infection
100%
Burkholderia pseudomallei
20%
Antibiotics
20%
In Vitro
20%
Outpatient
20%
Mortality Rate
20%
Yersinia Pestis
20%
Health Care
20%
Ceftazidime
20%
Amoxicillin
20%
Gram-Negative Bacteria
20%
Burkholderia mallei
20%
Bacillus Anthracis
20%
Francisella Tularensis
20%
Oral Drug Administration
20%
Topoisomerase
20%
Septicemia
20%
Pharmacology, Toxicology and Pharmaceutical Science
Infectious Agent
100%
Infection
100%
Melioidosis
100%
Burkholderia pseudomallei
20%
Antibiotics
20%
Mortality Rate
20%
Mouse
20%
Yersinia Pestis
20%
Francisella Tularensis
20%
Ceftazidime
20%
Amoxicillin
20%
Bacillus Anthracis
20%
Septicemia
20%
Burkholderia mallei
20%
Gram Negative Bacterium
20%